Knight Therapeutics Inc. signed a license agreement with AstraZeneca PLC for exclusive rights to Movantik in Canada and Israel.
The financial terms of the agreement were not disclosed.
Under the terms of the deal, Knight Therapeutics will manage all commercial, regulatory and certain supply chain activities for the drug in Canada and Israel.
Movantik sales in Canada were $372,000 for the 10 months ending October, according to QuintilesIMS data.
The drug is approved in Canada for the treatment of opioid-induced constipation in adult patients with noncancer pain who have had an inadequate response to laxatives. It is awaiting regulatory approval in Israel and will be marketed as Moventig upon approval.